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LETTERS TO THE EDITOR
Protection Factors are Ratios
To the Editor:
In their abstract, Davenport et al (1997) state that ‘‘Results consistently
demonstrated that all the test sunscreens protected (against immunosup-
pression) beyond their designated protections factors.’’ Protection factors
are ratios by definition, and if the above statement by Davenport et al
(1997) means anything at all, it is that the sunscreens’ immune protection
factors were greater than their corresponding sun protection factors
(SPF). Chu et al (1998) restate their claim in their recent letter to the
Journal of Investigative Dermatology in which they also state that they did
not calculate immune protection factors in their original paper but would
have to concede, from their own data, that had they done so, as suggested
in letters by Gasparro (1998) and Wolf and Kripke (1998), these would
have been lower than the corresponding SPF. If the immune protection
factor is lower than the SPF, it is just not possible for sunscreens ‘‘to
protect beyond their designated protection factors.’’ The authors tested
products with SPF ranging from 3.6 to 5.7, and defend their original
conclusions by arguing that although ex vivo skin exposed to 5 minimal
erythema doses (MED) results in 50% immunosuppression, a sunscreen
of SPF 5 5 completely protects against immunosuppression when skin
is exposed to 5 MED. This is hardly surprising as 5 MED with an SPF of
5 is equivalent to 1 MED without a sunscreen, and 1 MED without
sunscreen almost certainly does not cause immunosuppression in their
model. All the authors can conclude from this analysis is that 1 MED
delivered to the skin, with or without sunscreen, is not immunosuppres-
sive. Furthermore, the UV dose-threshold for immunosuppression in
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PUVA Therapy and Human Papillomavirus Type 5 Detection in
Psoriasis
To the Editor:
Michel Favre et al reported in this Journal a high prevalence of human
papillomavirus 5 (HPV5) infection in psoriatic patients and proposed that
psoriasis is a reservoir for this virus (Favre et al, 1998). These conclusions
were based on (i) the presence of antibodies against HPV5 VLP in 24.5%
of 155 psoriatic patients, contrasting with the 2%–5% observed in the
two other groups (atopic dermatitis and renal transplant recipients); (ii)
the detection of HPV5 DNA sequences by nested polymerase chain
reaction in lesional and uninvolved skin of 91.9% psoriatic patients and
in no patient in the atopic dermatitis group, respectively.
These results are very exciting but we question whether the high
prevalence of HPV5 infection is related to the psoriasis itself or to a
possible irradiation with ultraviolet (UV) via phototherapy. Indeed,
Bayle-Lebey et al have already reported the detection of HPV5 DNA
sequences in a keratosic skin lesion in a psoriatic patient, although this
patient had been treated for a long time with UVA phototherapy (Bayle-
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their in vitro assay is at least 3 MED. Therefore any sunscreen that protects
against erythema will protect against immunosuppression if tested using
their model. In order to evaluate an endpoint, one has to give a UVR
dose (with and without sunscreen) that induces the endpoint (e.g., 50%
immunosuppression). For example, it would be impossible to assess SPF
without giving an erythemal dose. In their recent letter, Chu et al express
concern about the possibility of sunscreens giving better protection
against erythema than immunosuppression, but the only way to evaluate
this legitimate concern is to compare immune protection factor with
SPF. Any conclusions on photoprotection (of any endpoint) without the
use of ratios will depend on the sensitivity of the assay and are therefore
invalid. In this context, it is worth stating that the SPF of the products
tested were determined in vitro and it is well known that such determina-
tions do not necessarily accord with in vivo assessments.
In summary, we totally agree with the letters by Gasparro (1998) and
Wolf and Kripke (1998), that the data of Davenport et al (1997) do not
show that sunscreens protect against immunosuppression beyond their
designated protection factors; in fact their data show exactly the opposite.
Antony Young, Susan L. Walker
Department of Photobiology, St John’s Institute of Dermatology, St
Thomas’s Hospital, London, U.K.
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Lebey et al, 1994). Unfortunately, data on the previous treatments of
Favre psoriatic patients are unknown. Moreover, the reported detection
ofHPVDNAsequences inboth involved andnonlesional skin inpsoriatic
patients suggests the role of an extrinsic factor such as UV.
The role of UV in epidermodysplasia verruciformis (EV) is well known
(Orth, 1987), and excessive sun exposure is avoided in EV patients.
Pityriasis versicolor-like skin lesions observed in EV and associated with
HPV infection are particularly located in sun-exposed areas. The role of
UV is clearly demonstrated in the induction of HPV5-associated skin
carcinomas in EV and in renal transplant recipients.
Few data are available concerning the search of EV-associated HPV
infection in patients under phototherapy. Spradbrow et al reported the
presence of a possible papillomavirus in sun-exposed skin (Spradbrow
et al, 1983); but most reported data are related to HPV16.
UV may act either via a local immunosuppression that could facilitate
HPV DNA replication, or transcription of HPV. It can be hypothesized
that EV-related HPV are widespread and that some factors such as local
(UV) or general immunosuppression (EV, immunosuppressive agents,
AIDS) may facilitate their replication and/or persistence.
On the other hand, it is difficult to understand the general good
efficiency of phototherapy in psoriatic patients and its detrimental effect
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in EV patients if EV-related HPV play a pathogenic role in these two
disorders. If the high prevalence of EV-related HPV in psoriasis was
confirmed, the use of phototherapy or immunosuppressive agents might
be reconsidered.
It would be of interest to look for an HPV5 infection in other skin
disorders such as mycosis fongoid or prurigo, which are currently treated
with phototherapy.
Emmanuel Mahe, Vincent Descamps
Department of Dermatology, Bichat Hospital, Paris, France
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Reply:
In response to the letter by Mahe´ and Descamps, we wish to discuss
further certain important problems raised by our study on psoriasis
(Favre et al, 1998).
The first question is whether the presence of HPV5 and other
epidermodysplasia verruciformis (EV)-associated HPV genotypes in
psoriatic lesions is related to the disease itself or to phototherapy acting
via a local immunosuppression. As shown in Table I, only 17 of the
37 patients previously studied both serologically and virologically were
currently under PUVA therapy (doses of UVA irradiation between 1
and 212 J per cm2), and six had received a treatment 1–11 y before
(doses between 40 and 150 J per cm2). The prevalence of anti-HPV5
antibodies and the detection rate of HPV5 DNA were similar among
the 23 patients receiving or having received PUVA therapy (26.1%
and 91.3%, respectively) and among the 14 untreated patients (28.6%
and 92.8%, respectively). Furthermore, HPV5-positive specimens of
uninvolved skin (Favre et al, 1998) were collected from unexposed
areas. The data strongly argue against phototherapy playing a role in
the persistence and expression of HPV5 in psoriasis. Our data on the
lack of detection of HPV5 in patients suffering from atopic dermatitis
(prurigo), a disease frequently treated by photochemotherapy, further
strengthen this conclusion.
A second important problem is the actual role played by HPV5 and
EV HPV in the increased and dose-dependent risk of nonmelanoma
skin cancer associated with PUVA therapy. Such a role could be
suggested by the case described by Bayle-Lebey et al (1994) and by
the data recently reported by Harwood et al (1998). In the latter study,
40% of the specimens of dysplastic keratoses and 50% of the specimens
of invasive carcinomas taken from patients treated by PUVA therapy
with high doses of UVA (essentially psoriasis patients) were found to
harbor EV HPV DNA, using highly sensitive nested polymerase chain
reaction methods. Similar or even higher rates of EV HPV detection
have been reported for precancerous skin lesions and nonmelanoma
skin cancers, for plucked hairs, and for specimens of normal skin
from immunocompetent individuals or immunosuppressed allograft
recipients (Boxman et al, 1997; Pfister and ter Schegget, 1997; Astori
et al, 1998). It is interesting to stress that, in contrast with its rare
detection in these studies, HPV5 was the EV HPV genotype most
frequently detected in dysplastic keratoses and skin carcinomas associated
with PUVA therapy (Harwood et al, 1998). Evidence available thus
demonstrates that EV HPV are widespread but, in the absence of any
data on the expression of the viral genome, their role in skin
carcinogenesis in non-EV patients remains unclear.
A third problem raised by Mahe´ and Descamps is the opposite
Table I. HPV5 status and PUVA therapy in psoriatic patientsa
Proportion of patients
PUVA treatment HPV5 seropositive HPV5 DNA positive
Present 4/17 16/17
Previous 2/6 5/6
None 4/14 13/14
aThirty-seven patients virologically studied in Favre et al (1998).
effects of UV radiations in EV and psoriasis, although both diseases are
associated with a high prevalence of HPV5. EV results from a genetic
predisposition to infection by the oncogenic HPV5 and related
genotypes. Numerous copies of HPV5 genome and abundant transcripts
of the E6 and E7 viral oncogenes are detected in EV benign lesions
and squamous cell carcinomas (Orth, 1987). Ultraviolet radiations of
sunlight may favor the persistence of EV lesions by their
immunosuppressive effect and, by inducing mutations within oncogenes
or tumor suppressor genes (like the p53 gene), may lead to the early
development of skin cancers, in synergy with the E6 and E7 viral
oncogenes. In contrast, HPV5 sequences are only detected in low
amounts in psoriatic lesions and no data are yet available on the
expression of the E6 and E7 viral genes. The detection of antibodies
against L1 and L2 capsid proteins in a significant proportion of patients,
however, can only be explained by the occurrence of a complete life
cycle of the virus in some keratinocytes (Favre et al, 1998; Majewski
et al, 1988). UV radiations and photochemotherapy have a beneficial
effect in patients with psoriasis, due to their immunosuppressive and
anti-proliferative actions. Because HPV5 infection is likely to be
favored by epidermal cell hyperproliferation (Majewski et al, 1998), it
can be assumed that phototherapy has a negative effect on HPV5
persistence and expression. It should be stressed that cases of psoriasis
selected for PUVA therapy are those active and extensive, in whom
epidermal proliferation may have already allowed a significant level of
viral expression.
Immunosuppressive therapies are methods of choice in the treatment
of psoriasis (Stern, 1997), and we strongly believe that the use of
phototherapy and immunosuppressive agents should not be
reconsidered because of HPV5 detection. They are the best treatment
modalities for decreasing T cell activation as well as epidermal
hyperproliferation, and, thus, expression and replication of EV HPV.
Michel Favre, Ge´rard Orth
Department of Virology, Institut Pasteur, Paris, France
Slavomir Majewski, Stefania Jablonska
Department of Dermatology, Warsaw School of Medicine, Warsaw,
Poland
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